Alpha 2.0
Login Register
» Authors » Trine Wellov Boesgaard

Trine Wellov Boesgaard

Explore the profile of Trine Wellov Boesgaard including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 520
Followers 0
Related Specialties
Endocrinology
General Medicine
Cardiology & Vascular Diseases
Top 10 Co-Authors
Torben Hansen
Oluf Pedersen
Markku Laakso
Ulf Smith
Henrik Wiggers
Jacob Eifer Moller
Brian Nilsson
Anders Jorsal
Allan Flyvbjerg
Norbert Stefan
Published In
Diabetes
J Clin Endocrinol Metab
Eur J Heart Fail
Ugeskr Laeger
BMJ Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, et al.
Diabetes Care . 2024 Jun; 47(8):1350-1359. PMID: 38907683
Objective: To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes. Research Design And Methods: In a multicenter, double-blind trial,...
2.
Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
Khunti K, Mohan V, Jain S, Boesgaard T, Begtrup K, Sethi B
Diabetes Ther . 2017 Mar; 8(3):673-682. PMID: 28332144
Introduction: The efficacy and safety of insulin degludec/liraglutide (IDegLira) has been evaluated in the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) phase 3 clinical trial...
3.
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
Jorsal A, Kistorp C, Holmager P, Tougaard R, Nielsen R, Hanselmann A, et al.
Eur J Heart Fail . 2016 Oct; 19(1):69-77. PMID: 27790809
Aims: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes. Methods And Results: LIVE...
4.
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
Holst J, Buse J, Rodbard H, Linjawi S, Woo V, Boesgaard T, et al.
J Diabetes Sci Technol . 2015 Oct; 10(2):389-97. PMID: 26443290
Objective: IDegLira is a novel, fixed-ratio combination of the long-acting basal insulin, insulin degludec, and the long-acting glucagon-like peptide-1 analog liraglutide. We studied the effect of IDegLira versus its components...
5.
A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
Jorsal A, Wiggers H, Holmager P, Nilsson B, Nielsen R, Boesgaard T, et al.
BMJ Open . 2014 May; 4(5):e004885. PMID: 24844271
Introduction: Heart failure is one of the most common cardiovascular complications of diabetes and the most disabling and deadly complication too. Many antidiabetic agents have been associated with increased morbidity...
6.
Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity
Dimas A, Lagou V, Barker A, Knowles J, Magi R, Hivert M, et al.
Diabetes . 2013 Dec; 63(6):2158-71. PMID: 24296717
Patients with established type 2 diabetes display both β-cell dysfunction and insulin resistance. To define fundamental processes leading to the diabetic state, we examined the relationship between type 2 diabetes...
7.
Insulin gene mutations resulting in early-onset diabetes: marked differences in clinical presentation, metabolic status, and pathogenic effect through endoplasmic reticulum retention
Meur G, Simon A, Harun N, Virally M, Dechaume A, Bonnefond A, et al.
Diabetes . 2009 Dec; 59(3):653-61. PMID: 20007936
Objective: Heterozygous mutations in the human preproinsulin (INS) gene are a cause of nonsyndromic neonatal or early-infancy diabetes. Here, we sought to identify INS mutations associated with maturity-onset diabetes of...
8.
Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients--EUGENE2 study
Boesgaard T, Gjesing A, Grarup N, Rutanen J, Jansson P, Letizia Hribal M, et al.
PLoS One . 2009 Oct; 4(9):e7236. PMID: 19789630
Background: A meta-analysis combining results from three genome-wide association studies and followed by large-scale replication identified six novel type 2 diabetes loci. Subsequent studies of the effect of these variants...
9.
[Diabetes in infants may be treated with sulfonylurea as a replacement for insulin]
Lauridsen M, Boesgaard T, Pedersen O, Hansen T, Hertz B
Ugeskr Laeger . 2009 Jun; 171(23):1923-4. PMID: 19500515
A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested...
10.
Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance
Stancakova A, Pihlajamaki J, Kuusisto J, Stefan N, Fritsche A, Haring H, et al.
J Clin Endocrinol Metab . 2008 Feb; 93(5):1924-30. PMID: 18285412
Context: CDKAL1 is a recently discovered susceptibility gene for type 2 diabetes. Objective: Our objective was to investigate the impact of rs7754840 of CDKAL1 on insulin secretion, insulin sensitivity, and...